Preliminary Results from a Randomized, Open-Label, Phase 2 Study of Botensilimab (BOT) with or Without Balstilimab (BAL) in Refractory Microsatellite Stable Metastatic Colorectal Cancer with No Liver Metastases (MSS Mcrc NLM).
Journal of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined